Efficacy and safety of a raltegravir containing antiretroviral regimen among human immunodeficiency virus infected patients on methadone maintenance therapy
10.3760/cma.j.issn.1000-6680.2017.06.007
- VernacularTitle:拉替拉韦在接受美沙酮替代治疗的人类免疫缺陷病毒阳性者有效性及安全性评价研究
- Author:
Yao ZHANG
;
Ronghui XIE
;
Huiqing LI
;
Lian YANG
;
Xia LIU
;
Zhihui DOU
;
Fujie ZHANG
- Keywords:
Human immunodeficiency virus;
Methadone;
Antiretroviral therapy;
Injection drug user
- From:
Chinese Journal of Infectious Diseases
2017;35(6):352-356
- CountryChina
- Language:Chinese
-
Abstract:
Objective To explore the efficacy and safety of a raltegravir (RAL)-containing regimen among patients on methadone maintenance therapy.Methods From January 2010 to November 2010, 30 virus (HIV) treatment naive patients who were on methadone maintenance therapy were enrolled from a HIV clinic in Kunming, Yunnan Province and a HIV clinic in Hengyang, Hunan Province.All patients were given RAL, tenofovir (TDF) and lamivudine (3TC) as highly active antiretroviral therapy (HARRT).Patients were followed up for 48 weeks to evaluate the adjustment of methadone dose, opiate withdrawal reaction, antiretroviral efficacy and safety.Results From January 2010 to November 2010, 30 HIV patients were enrolled from the two appointed HIV clinics.The mean age was 39±6 years, with 73.3% male patients and 97% Han population.Before the treatment, their mean CD4+T lymphocyte counts was 210 /μL.Ninety percent of patients were co-infected with hepatitis C.Twenty-nine patients who completed study follow-up were included in final analysis.Five (17.8%) patients reported opiate withdrawal symptoms and increased methadone dose 4 weeks after HARRT.At 24 weeks and 48 weeks of HARRT, the average increase of CD4+T lymphocyte counts were (136±71) /μL and (185±88)/μL, respectively.Among patients who provided valid HIV-1 RNA testing results, 82.6% (19/23) and 95.8% (23/24) of patients had undetectable viral load at week 24 and week 48.Six grade 1-2 adverse events were reported in 4 patients.Conclusions In this pilot study, the new regimen containing RAL, TDF and 3TC appears to be an ideal option for patients on methadone maintenance therapy, because of its limited impact on methadone dose and good efficacy and safety profile.
